Medicare's Coverage of Valganciclovir

Medicare Part B covers valganciclovir when prescribed by your doctor for cytomegalovirus (CMV) infection, but only under specific conditions. The drug is covered as an injectable or oral medication when medically necessary, and your doctor must document that it treats an active CMV infection — most commonly in people with weakened immune systems, including those with HIV/AIDS or those who have had an organ transplant.

Coverage depends on where you receive the medication. If valganciclovir is given intravenously in a hospital outpatient setting or doctor's office, Medicare Part B pays for it directly. If you take it as an oral medication at home, it falls under Part D (prescription drug coverage), which means your coverage and costs depend on which Part D plan you have chosen.

The key distinction is that Medicare does not cover valganciclovir for prevention of CMV infection in most cases — only for treatment of active disease. If your doctor prescribes it preventively after a transplant or due to low CD4 counts, you will need to check with Medicare or your plan to confirm coverage for your specific situation.

Key Takeaways

  • Valganciclovir is covered by Medicare Part B when given as an injection in a medical setting, and by Part D when taken as an oral medication at home.
  • Medicare covers the drug only when prescribed to treat an active CMV infection, not to prevent it, though preventive use may be covered in some transplant situations.
  • Your out-of-pocket cost depends on whether you have Part D coverage and which plan you chose, as costs vary widely between plans.
  • Your doctor's office or pharmacy can contact Medicare or your Part D plan to confirm coverage before you fill the prescription.

How Part B and Part D Coverage Works for This Drug

When valganciclovir is administered intravenously in a hospital outpatient department, ambulatory surgery center, or doctor's office, Medicare Part B covers the drug itself as well as the administration fee. You pay 20 percent of the Medicare-approved amount after you have met your Part B deductible. This route is common for people with severe CMV infections who need rapid treatment.

If your doctor prescribes oral valganciclovir tablets to take at home, the drug is covered under your Part D prescription drug plan instead. Your cost depends entirely on which plan you chose during open enrollment. Some plans cover valganciclovir with a standard copay; others place it on a higher tier and charge a larger copay or coinsurance. A few plans may require prior authorization before the pharmacy can fill it, meaning your doctor must submit paperwork to the plan first.

If you do not have Part D coverage, you will pay the full pharmacy price out of pocket, which can be several hundred dollars per month. Enrolling in Part D during the annual open enrollment period (October 15 to December 7) or within 63 days of losing other drug coverage can prevent this gap.

When Medicare Covers Valganciclovir and When It Does Not

Medicare covers valganciclovir when your doctor documents that you have an active CMV infection that requires treatment. The most common scenarios are CMV retinitis (an eye infection) in people with advanced HIV, CMV colitis or esophagitis in immunocompromised patients, and CMV disease following organ or bone marrow transplant. In each case, your doctor must show that the infection is present and that valganciclovir is medically necessary.

Medicare does not routinely cover valganciclovir when prescribed solely to prevent CMV infection, even in high-risk patients such as those with CD4 counts below 50 cells or those awaiting transplant. However, some transplant centers have obtained coverage for preventive valganciclovir in the when ready post-transplant period by submitting a detailed medical justification. This is not automatic and requires your doctor to request it.

If your doctor prescribes valganciclovir for a use that Medicare does not typically cover, ask whether they can document medical necessity or whether an appeal is possible. Some denials can be overturned if your doctor provides additional clinical evidence.

What to Do Before Filling Your Prescription

Before you go to the pharmacy, ask your doctor's office to verify coverage with Medicare or your Part D plan. This takes one to two business days and can prevent you from arriving at the pharmacy only to learn the prescription is not covered or requires prior authorization. Provide your Medicare number and, if you have Part D, your plan name and member ID.

If you have Part D, ask your pharmacy to check your plan's formulary (the list of covered drugs) and your tier level for valganciclovir. This tells you exactly what your copay or coinsurance will be. If the cost is higher than you expected, your doctor may be able to request a formulary exception — a request for the plan to cover the drug at a lower tier — though approval is not may provide.

If your doctor's office says Medicare has denied the prescription, ask for the denial letter and the reason. Common reasons include lack of documentation of active CMV infection or use for prevention rather than treatment. Your doctor can appeal the denial by submitting additional medical records or a letter explaining why the drug is medically necessary in your case.

Cost and Out-of-Pocket Expenses

If valganciclovir is given intravenously in a medical setting, you pay 20 percent of the Medicare-approved amount after your Part B deductible. The Medicare-approved amount varies but typically ranges from several hundred to over a thousand dollars per dose, depending on the dose and frequency. For a course of treatment lasting weeks or months, your total out-of-pocket cost can be substantial.

For oral valganciclovir covered under Part D, your cost is your plan's copay or coinsurance. This ranges from $10 to $50 per month on lower tiers, but can exceed $100 per month on higher tiers. If you reach your plan's out-of-pocket maximum during the year, Medicare covers 95 percent of costs for the rest of the year, and you pay only 5 percent.

If cost is a barrier, ask your doctor whether a lower-cost alternative exists or whether the drug manufacturer offers a patient information program. Some manufacturers reduce or waive copays for uninsured or underinsured patients, though you must meet income requirements.

Appealing a Medicare Denial

If Medicare or your Part D plan denies coverage for valganciclovir, you have the right to appeal. For Part B denials, you can file a redetermination request within 120 days of the denial notice. For Part D denials, you can request a coverage information review within the same timeframe. Both processes require submitting the denial letter and any additional medical documentation your doctor believes supports coverage.

Your doctor's office can submit the appeal on your behalf, or you can do it yourself by contacting Medicare directly at 1-800-MEDICARE or through your Part D plan's customer service number. Include a letter from your doctor explaining why valganciclovir is medically necessary for your specific condition. Appeals often succeed when the initial denial was based on incomplete information.

If the appeal is denied, you can request a hearing before an administrative law judge, though this process takes several months. Many people continue treatment while the appeal is pending, either by paying out of pocket or by asking their doctor whether a covered alternative is available.

Frequently Asked Questions

Does Medicare cover valganciclovir for CMV prevention after a transplant?

Medicare does not automatically cover preventive valganciclovir, but some transplant centers have obtained coverage by submitting a detailed medical justification to Medicare. Ask your transplant team whether they have done this for your situation. If not, you may need to pay out of pocket or ask whether a covered alternative exists.

What if my Part D plan does not cover valganciclovir?

You can request a formulary exception from your plan, asking them to cover the drug at a lower tier or to waive prior authorization requirements. Your doctor must submit this request, and the plan has 72 hours to respond. If denied, you can appeal or switch to a different Part D plan during open enrollment if valganciclovir is covered there.

Can I get valganciclovir covered if I have Original Medicare without Part D?

If your doctor prescribes oral valganciclovir and you have no Part D coverage, Medicare does not cover it. You would pay the full pharmacy price. You can enroll in Part D during open enrollment or within 63 days of losing other drug coverage to gain coverage going forward.

How long does it take Medicare to approve valganciclovir coverage?

If your doctor submits a prior authorization request for Part D coverage, the plan typically responds within 24 to 72 hours. For Part B coverage of intravenous valganciclovir, approval is usually when ready if your doctor's documentation is complete. Delays usually occur when the plan requests additional medical records.

What should I do if I cannot afford the copay for valganciclovir?

Contact the drug manufacturer to ask about patient information programs, which may reduce or waive your copay if you meet income limits. You can also ask your doctor whether a generic version or lower-cost alternative is available, or whether your state has a pharmaceutical information program for people with limited income.